Table 2 Correlations between PYGO2 and IL10 gene expression and clinicopathological characteristics of ESCC patients
From: PYGO2 regulates IL10 and plays immunosuppressive role through ESCC progression
PYGO2 | IL10 | |||||
|---|---|---|---|---|---|---|
Clinicopathology | N/U* | O | N/U | O | ||
Sex | Male | 21 | 11 | 15 | 17 | |
Female | 19 | 7 | 13 | 13 | ||
Node metastasis | No metastasis | 22 | 11 | 13 | 20 | |
Node metastasis | 18 | 7 | 15 | 10 | ||
Depth of invasion | T1 and T2 | 8 | 3 | 6 | 5 | |
T3 and T4 | 32 | 15 | 22 | 25 | ||
Stage of progression | Stages I and II | 26 | 11 | 16 | 21 | |
Stages III and IV | 14 | 7 | 12 | 9 | ||
Grade of differentiation | P.D** | 6 | 5 | 5 | 6 | |
M.D | 25 | 10 | 16 | 19 | ||
W.D | 9 | 3 | 7 | 5 | ||
Tumor location | Lower | 14 | 9 | 10 | 13 | |
Middle | 25 | 9 | 17 | 17 | ||
Upper | 1 | 0 | 1 | 0 | ||